Asian Oncol Nurs.  2013 Dec;13(4):210-221. 10.5388/aon.2013.13.4.210.

A Study on Vascular Pain Due to Gemcitabine and According to Clinical Factors

• Seong SR
• Lee N
• Lee MJ
• Jang HA
• Song MJ
• Park SJ
• Kim J
• Ryoo BY

• KMID: 2269478
• DOI: http://doi.org/10.5388/aon.2013.13.4.210

Abstract

PURPOSE
This study was performed to examine vascular pain due to gemcitabine and according to clinical factors.
METHODS
The survey was performed with 525 cancer patients visiting chemotherapy infusion room in one general hospital. The data were collected via self-reported questionnaire, researchers observation, and reviewing medical records. Data were analyzed descriptive statistics, t-test, Kruskal-Wallis test, Tukey test using ranks, Jonckheere-Terpstra test, and Spearman correlation analysis were used.
RESULTS
The mean scores of the intensity and onset time of vascular pain were 3.06+/-2.16 and 8.13+/-13.13 min, and each other were negative correlaton. Degree of intensity of vascular pain had a significant difference on gender (p=.003), age (p=.004), weight (p=.019), Body mass index (BMI) (p=.005), Body surface area (BSA) (p=.030), infusion time (p<.001), dose (p=.027), dose per minute (p<.001), the number of administered gemcitabine (p=.005), combination chemotherapeutic drug (p=.013) and tumor type (p=.002). Degree of onset time of vascular pain had a significant difference on infusion time (p=.044), combination chemotherapy (p=.001) and injection site (p=.001).
CONCLUSION
Patients administrated gemcitabine were experiencing various vascular pain, and vascular pain had a difference on clinical factors. Therefore, oncology nurses should be considered significant clinical factors to implement effective interventions to patients administered gemcitabine.

Keyword

Gemcitabine; Vascular; Pain; Neoplasms

MeSH Terms

Body Mass Index
Body Surface Area
Drug Therapy
Drug Therapy, Combination
Hospitals, General
Humans
Medical Records
Surveys and Questionnaires

Reference

1. National Cancer Information Center. National cancer registraion statistics. Accessed October 10, 2013. http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040101000000.

2. Yabro CH, Frogge MH, Goodman M, Groenwald SL. Cancer nursing principles and practice. 5th ed. Sudbury: Jones and bartlett Publishers;2000.

3. Yun YH, Kwak MY, Park SM, Kim SY, Choi JS, Lim HY, et al. Chemotherapy Use and Associated Factors among Cancer Patients near the End of Life. Oncology. 2007; 72:164–171.

4. Lilly. Prescribing information from the FDA about GEMZAR (gemcitabine). Accessed March 3, 2013. http://pi.lilly.com/us/gemzar.pdf.

5. Wilkes GM, Barton-burke M. Oncology Nursing Drug Handbook. Jones and Bartlett Publishers: sudbury;2011.

6. Diedra L. Drug information handbook for oncology. 11th ed. hudson: Lexicomp publishers;2013.

7. Asan Medical Center. Asan medical information statistics. Accessed April 3, 2013. http://itsm.amc.seoul.kr/ck2s/login.do.

8. In : Yu CS, editor. Proceedings of the 9th conference of Korean society of clinical oncology. Korean society of clinical oncology autumn conference 2013; 2013 Oct 5; Ilsan, Korea. Seoul: Pentaid;2013.

9. Jordan K, Grothe W, Schmoll HJ. Extravasation of chemotherapeutic agents: Prevention and therapy. Dtsch Med Wochenschr. 2005; 130:33–37.

10. Ener RA, Meglatheryl SB, Styler M. Extravasation of systemic hematooncological therapies. Ann Oncol. 2004; 15:858–862.

11. Ian NO. The MASCC Textbook of cancer supportive care and survivorship. LA: Springer;2011.

12. Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol. 2006; 33(1):139–143.

13. Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf. 2008; 7(6):703–716.

14. Ok SY, Shin TC, Baek YH, Kim SH, Kim SI, Kim SC, et al. Comparision of the preventing effect of lidocaine dose and injection timing for prevention of rocuronium bromide injection pain. J Soonchunhyang Med Coll. 2008; 14:109–115.

15. Kang WJ, Hong SK, Kim KS. Effect of ondansetron and lidocaine on vascular pain associated with intravenous propofol injection. Korean J Anesthesiol. 2004; 46:393–396.

16. Lee JT, Yoo KY, Jeong CY. Effect of lidocaine on pain caused by intravenous injection of (diazepam). Korean J Anesthesiol. 1992; 25:582–588.

17. Yatate M, Kimura M, Iwasaki Y, Kamura M, Yokoi M, Uchitani S, et al. Reduction of vascular pain due to drop-infusion of oxaliplatin (L-OHP)in peripheral vein with heated infusion route. Gan To Kagaku Ryoho. 2012; 39(4):589–591.

18. Nakashima T, Ogawa Y, Kimura A, Kido M, Okikawa Y, Ito T, et al. Coadministration of 5% glucose solution has a decrease in bendamustine-related vascular pain grade. J Oncol Pharm Pract. 2012; 18(4):445–447.

19. Ono C, Yamagami M, Kamatani R, Yamamoto M, Mukouyama T, Sugimoto M, et al. Promising new injection method to prevent angialgia/phlebitis from epirubicin hydrochloride therapy for breast cancer. Gan To Kagaku Ryoho. 2012; 39(5):777–781.

20. Hosokawa A, Nakashima T, Ogawa Y, Kozawa K, Kiba T. Coadministration of 5% gluco-se solution relieves vascular pain in the patients administered gemcitabine immediately. J Oncol Pharm Pract. 2013; 19(2):190–192.

21. SPSS Paper Statistics Translation Space. Prescribing information of SPSS statistical bases. Accessed March 3, 2013. http://cafe.naver.com/spssqueen/705.

22. National Cancer Center Pain Committee. Pain Management Guideline. 5th ed. Gyeonggi-do: National Cancer Information Center Publishers;2013.

23. ChosunMedia. News account from the Healthchosun. Accessed September 2,2013. Available from: http://health.chosun.com/site/data/html_dir/2005/09/29/2005092956040.html.

24. Donovan KA, Taliaferro LA, Brock CW, Bazargan S. Sex differences in the adequacy of pain management among patients referred to a multidiciplinary cancer pain clinic. J Pain Symptom Manage. 2008; 36:167–172.

25. Kim DH, Lee KH, Cho DS, Jeong HJ, Kim JH, Lee SA, et al. Relationship between pain threshold and postoperative morphine requirement. Korean J Anesthesiol. 2004; 46:430–433.

26. Edwards RR, Fillingim RB, Yamauchi S, Sigurdsson A, Bunting S, Mohorn SG, et al. Effects of gender and acute dental pain on thermal pain responses. Clin J Pain. 1999; 15:233–237.

27. Woodrow KM, Friedman GD, Siegelaub AB, Collen MF. Pain tolerance: Differences according to age, sex and race. Psychosom Med. 1972; 34:548–556.

28. Turk DC, Okifuji A, Scharff L. Chronic pain and depression: role of perceived impact and perceived control in different age cohorts. Pain. 1995; 61:93–101.

29. Virani T. Care and Maintenance to Reduce Vascular Access Complications. Toronto: Blackwell Publisher;2005.

30. Kawar P, Dundee JW. Frequency of pain on injection and venous sequelae following the I.V. administration of certain anaesthetics and sedatives. Br J Anaesth. 1982; 54(9):935–939.